Vaccine and Infectious Disease Division
Prevention strategies and therapeutic options for many viruses are currently inadequate for the successful reduction of disease prevalence, especially in resource-poor settings. VIDD is home to one of the world’s largest vaccine programs that includes vaccine development and clinical trial studies. Several VIDD disciplines, such as virology, epidemiology and statistics, work in concert with the common goal of curbing viral infection.
Research interests include early innate immune responses to HIV vaccines on subsequent adaptive immune responses and systems biology analyses of how immune responses are shaped
Research interests include targeting latent viral genomes for mutagenesis and disruption of viral pathogenesis and infection using engineered homing endonucleases.
Infections in the immunocompromised host, especially diagnosis, prevention and treatment of CMV, VZV, BK virus, adenovirus, and respiratory virus infections. Research includes understanding the genetic basis of infeciton complications, genome and gene expression studies.
Phone: (206) 667-4898
Fax: (206) 667-4411
Epidemiology, natural history, and treatment of human herpesvirus 8 infection and treatment of Epstein Barr Virus-associated lymphomas. HIV-related cance and infections as a complication of cancer care. Cancer epidemiology, pathobiology, treatment and training in resource-limited settings.
Phone: (206) 667-4600
Fax: (206) 667-1965
Characterizing T cells induced by candidate vaccines using flow cytometry. Developing new assays to evaluate vaccine efficacy with HIV Vaccine Trials Network. Studies include examining T cell function at the single-cell level using advanced flow cytometric techniques; examples include T cell responses to vaccination and to viral infections such as CMV, EBV, HIV, and hepatitis B.
Elucidating cellular mechanisms for control of HIV replication, Assessing cellular immune responses in HIV vaccine recipients, Teaching and Mentoring Interests, HIV immunology for experts and the public
Immunology and vaccine design for development of vaccines, especially HIV-1 vaccine
Clinically important persistent and latent viral infections; curative therapies for latent viral infections ;diagnosis of disease caused by herpesviruses, enterovirus, JC and BK viruses, parvovirus B19, and hepatitis viruses
Phone: (206) 667-6793
Fax: (206) 667-6179
HIV and tuberculosis (Tb) vaccine research and development, human challenge experiments, microbiome modulation of immunity, immune activation—polymicrobial infections, combination HIV prevention, malaria clinical trials/vaccines and molecular epidemiology
Roles of regulatory T cells in modulating anti-viral immunity; anti-viral immunity; vaccine development
Laboratory diagnosis of viral disease in humans.
Natural history and epidemiology of genital herpes and neonatal herpes.
Fax: (206) 667-6366
Interest in describing the quantitative and dynamical features of human pathogens and immune responses. Most of work to-date is on the pathogenesis of HSV-2 infection but also interested in applying models to optimize viral eradication startegies, and to use models to capture kinetic features of the human microbiome.
Epidemiology, natural history, therapy, and prevention of HSV and other herpesvirus infections; interactions between HSV and HIV Vaccines and clinical trials
Phone: (206) 520-4340
Research focus includes analysis of HIV-1 CFSE assay data, cross-protocol analysis of DNA and Pox exploratory analysis and statistical methods for viral load set points
Phone: (206) 667-7008
Fax: (206) 667-4378